As submitted to the Securities and Exchange Commission on April 28, 2025

 

Registration No. 333-262631

Registration No. 333-255041

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

POST-EFFECTIVE AMENDMENT No. 5

And

POST-EFFECTIVE AMENDMENT No. 6 to

FORM S-1

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

KRAIG BIOCRAFT LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

 

Wyoming   7372   83-0459707
(State or other jurisdiction of
incorporation or organization)
  (Primary Standard Industrial
Classification Code Number)
  (I.R.S. Employer
Identification Number)

 

2723 South State St. Suite 150

Ann Arbor, Michigan 48104

Tel. (734) 619-8066

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Kim Thompson, CEO

Kraig Biocraft Laboratories, Inc.

2723 South State St., Suite 150, Ann Arbor, Michigan 48104

(734) 619-8066

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

With a Copy to:

 

Louis Taubman, Esq.
Hunter Taubman Fischer & Li LLC

950 Third Avenue, 19th Floor

New York, NY 10022

(212) 530-2210

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Exchange Act. ☐

 

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to such Section 8(a), may determine.

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Post-Effective Amendment (the “Pos-Am”) to the Registration Statement on Form S-1 (File No. 333-262631), initially filed on February 12, 2022, and declared effective on April 8, 2022, is being filed as an exhibits-only filing, to file an updated auditor consent. Accordingly, this amendment consists only of the facing page, this explanatory note, Item 16(a) of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibit. The remainder of the Registration Statement is unchanged and has therefore been omitted.

 

No additional securities are being registered under this Pos-Am. All applicable registration fees were previously paid.

 

 

 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item 16. Exhibits and Financial Statement Schedules.

 

(a) The following exhibits are filed as part of this Registration Statement:

 

EXHIBIT INDEX

 

EXHIBIT

NUMBER

  DESCRIPTION
     
3.1   Articles of Incorporation (1)
     
3.2   Articles of Amendment (3)
     
3.3   Articles of Amendment, filed with the Wyoming Secretary of State on November 15, 2013 (6)
     
3.4   Articles of Amendment, filed with the Wyoming Secretary of State on December 17, 2013 (7)
     
3.5   By-Laws (1)
     
4.1   Warrant issued Mr. Jonathan R. Rice (18)
     
4.2   Purchase Warrant (20)
     
4.3   Secured Convertible Debenture (20)
     
4.4   Warrant issued December 11, 2020 (19)
     
4.5   Secured Convertible Debenture dated December 11, 2020 (19)
     
4.6   Amended and Restated Convertible Debenture (20)
     
4.7   Form of Convertible Debenture dated January 18, 2022 (21)
     
4.8   Form of Warrant dated January 18, 2022 (21)
     
5.1   Opinion of Wyoming counsel, as to the validity of the Common Stock (22)
     
5.2   Opinion of US counsel, as to the validity of the Common Stock (22)
     
10.1   Employment Agreement, dated November 10, 2010, by and between Kraig Biocraft Laboratories, Inc. and Kim Thompson (8)
     
10.6   Addendum to the Founder’s Stock Purchase and Intellectual Property Transfer Agreement, dated December 26, 2006, and the Founder’s Stock Purchase and Intellectual Property Transfer Agreement dated April 26, 2006 (3)
     
10.7   Intellectual Property/Collaborative Research Agreement dated March 20, 2010, by and between Kraig Biocraft Laboratories and The University of Notre Dame du Lac. (2)
     
10.11   License Agreement dated October 28, 2011, between the Company and University of Notre Dame du Lac. (12)
     
10.12   Intellectual Property / Collaborative Research Agreement dated June 6, 2012, between the Company and University of Notre Dame du Lac. (12)
     
10.14   Employment Agreement, dated January 19, 2015, between the Company and Mr. Jonathan R. Rice (11)
     
10.15   Intellectual Property and Collaborative Research Agreements dated March 4, 2015, between the Company and University of Notre Dame du Lac. (14)
     
10.16   2019 Employee Stock Option Plan (15)
     
10.17   Strategic Partnership Agreement between the Company and Mthemovement Kings Pte Ltd. (17)

 

II-1

 

 

10.18   Amendment to Strategic Partnership Agreement between the Company and Mthemovement Kings Pte Ltd. (17)
     
10.19   Convertible Debenture (19)
     
10.20   Securities Purchase Agreement (19)
     
10.21   Securities Purchase Agreement (20)
     
10.22   Registration Rights Agreement (20)
     
10.23   Global Guaranty Agreement (20)
     
10.24   Security Agreement (20)
     
10.25   IP Security Agreement (20)
     
10.26   Form of Securities Purchase Agreement dated January 18, 2022 (21)
     
10.27   Form of Amended and Restated Guaranty Agreement January 18, 2022 (21)
     
10.28   Form of Amended and Restated Security Agreement January 18, 2022 (21)
     
10.29   Form of Amended and Restated IP Security Agreement January 18, 2022 (21)
     
10.30   Form of Registration Rights Agreement January 18, 2022 (21)
     
10.31   Standby Equity Purchase Agreement dated as of January 21, 2025, by and between the Company and YA II PN, LTD. (25)
     
14.1   Code of Business Conduct and Ethics (13)
     
14.2   Code of Ethics (16)
     

19.1

  Insider Trading Policy (23)

 

21.1   List of Subsidiaries (23)
     
23.1   Consent of M&K CPAS, PLLC *
     
23.2   Consent of U.S. counsel (included in Exhibit 5.2) (22)
     
23.3   Consent of Wyoming counsel (included in Exhibit 5.1) (22)
     
99.1   Form of Audit Committee Charter (16)
     
99.2   Form of Compensation Charter (16)
     
99.3   Form Nominating and Governance Charter (16)
     
107   Filing Fees Exhibit (24)
     
    XBRL for the Fiscal Years Ended December 31, 2024 *
101.INS   XBRL Instance Document *
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document *
101.SCH   XBRL Taxonomy Extension Schema Document *
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document *
101.LAB   XBRL Taxonomy Extension Labels Linkbase Document *
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document *

 

*Filed herewith

 

(1) Incorporated by reference to our Registration Statement on Form SB-2 (Reg. No. 333-146316) filed with the SEC on September 26, 2007.

(2) Incorporated by reference to our annual report on Form 10-K for the year ended December 31, 2009, filed with the SEC on April 15, 2010.

(3) Incorporated by reference to our Registration Statement on Form S-1 (Reg. No. 333-162316) filed with the SEC on October 2, 2009.

(4) Incorporated by reference to our Current Report on Form 8-K filed with the SEC on June 29, 2011.

(5) Incorporated by reference to our Quarterly Report on Form 10-Q filed with the SEC on May 15, 2013.

(6) Incorporated by reference to our Current Report on Form 8-K filed with the SEC on November 22, 2013.

(7) Incorporated by reference to our Current Report on Form 8-K filed with the SEC on December 19, 2013.

(8) Incorporated by reference to our Registration Statement on Form S-1 (Reg. No. 333-175936) filed with the SEC on August 1, 2011.

(9) Incorporated by reference to our Registration Statement on Form S-1 (Reg. No. 333-199820) filed with the SEC on November 3, 2014.

(10) Incorporated by reference to our Amendment No. 1 to Registration Statement on Form S-1/A (Reg. No. 333-199820) filed with the SEC on January 7, 2015.

(11) Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 21, 2015.

 

II-2

 

 

(12) Incorporated by reference to our Amendment No. 2 to Registration Statement on Form S-1/A (Reg. No. 333-199820) filed with the SEC on January 30, 2015.

(13) Incorporated by reference to Exhibit 14.1 to our Annual Report on Form 10-KSB for the year ended December 31, 2007, filed with the SEC on March 26, 2008.

(14) Incorporated by reference to Exhibit 10.15 to the Annual Report on Form 10-K filed on March 31, 2015.

(15) Incorporated by reference to our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 27, 2020.

(16) Incorporated by reference to our Registration Statement on Form S-1 (Reg. No. 333-238883) filed with the SEC on June 2, 2020.

(17) Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 26, 2021.

(18) Incorporated by reference to Exhibit 4.1 to the Annual Report on Form 10-K filed on March 31, 2015.

(19) Incorporated by reference to our Current Report on Form 8-K filed with the SEC on December 11, 2020.

(20) Incorporated by reference to our Current Report on Form 8-K filed with the SEC on March 26, 2021.

(21) Incorporated by reference to our Current Report on Form 8-K filed with the SEC on January 20, 2022.

(22) Incorporated by reference to our Registration Statement on Form S-1 (Reg. No. 333-262631) filed with the SEC on February 10, 2022.

(23) Reserved.

(24) Incorporated by reference to our Registration Statement on Form S-1 (Reg. No. 333-238883) filed with the SEC on April 14, 2022.

(25) Incorporated by reference to Exhibit 10.1 our Current Report on Form 8-K filed with the SEC on January 21, 2025.

 

Item 17. Undertakings.

 

The undersigned registrant hereby undertakes:

 

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

 

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

 

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

 

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(4) That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

II-3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, NY, on April 28, 2025.

 

  KRAIG BIOCRAFT LABORATORIES, INC.
     
  By: /s/ Kim Thompson
    President, Chief Executive Officer, and Chief Financial Officer
    (Principal Executive Officer and Principal Financial and Accounting Officer)

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Kim Thompson   President, Chief Executive Officer,   April 28, 2025
Kim Thompson   Chief Financial Officer and Sole Director    

 

II-4

 

 

 

 

Exhibit 23.1

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated March 28, 2025 relating to the financial statements which appeared in Kraig Biocraft Laboratories, Inc. Annual Report on Form 10K as of and for the years ended December 31, 2024 and 2023 and the reference to our firm under the caption “Experts” in the Registration Statement.

 

/s/ M&K CPA’s, PLLC

 

The Woodlands, TX

April 28, 2025